CN117049960A - Preparation method of crocetin and application of crocetin in antioxidation and eye protection - Google Patents
Preparation method of crocetin and application of crocetin in antioxidation and eye protection Download PDFInfo
- Publication number
- CN117049960A CN117049960A CN202210522534.5A CN202210522534A CN117049960A CN 117049960 A CN117049960 A CN 117049960A CN 202210522534 A CN202210522534 A CN 202210522534A CN 117049960 A CN117049960 A CN 117049960A
- Authority
- CN
- China
- Prior art keywords
- crocus sativus
- crocetin
- extract
- crocin
- hydrolysate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- PANKHBYNKQNAHN-JTBLXSOISA-N Crocetin Natural products OC(=O)C(\C)=C/C=C/C(/C)=C\C=C\C=C(\C)/C=C/C=C(/C)C(O)=O PANKHBYNKQNAHN-JTBLXSOISA-N 0.000 title claims description 49
- PANKHBYNKQNAHN-JUMCEFIXSA-N carotenoid dicarboxylic acid Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C(=O)O)C=CC=C(/C)C(=O)O PANKHBYNKQNAHN-JUMCEFIXSA-N 0.000 title claims description 49
- PANKHBYNKQNAHN-MQQNZMFNSA-N crocetin Chemical compound OC(=O)C(/C)=C/C=C/C(/C)=C/C=C/C=C(\C)/C=C/C=C(\C)C(O)=O PANKHBYNKQNAHN-MQQNZMFNSA-N 0.000 title claims description 49
- 230000003064 anti-oxidating effect Effects 0.000 title abstract description 3
- 239000000284 extract Substances 0.000 claims abstract description 46
- 239000000413 hydrolysate Substances 0.000 claims abstract description 38
- 230000007062 hydrolysis Effects 0.000 claims abstract description 23
- 238000006460 hydrolysis reaction Methods 0.000 claims abstract description 23
- 239000002253 acid Substances 0.000 claims abstract description 20
- 238000000605 extraction Methods 0.000 claims abstract description 17
- 210000000844 retinal pigment epithelial cell Anatomy 0.000 claims abstract description 14
- 230000004083 survival effect Effects 0.000 claims abstract description 5
- 244000124209 Crocus sativus Species 0.000 claims description 83
- 235000015655 Crocus sativus Nutrition 0.000 claims description 83
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 80
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 28
- 239000000843 powder Substances 0.000 claims description 25
- 239000007864 aqueous solution Substances 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 20
- 239000000243 solution Substances 0.000 claims description 18
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 11
- 238000001914 filtration Methods 0.000 claims description 9
- 239000001599 crocus sativus l. flower extract Substances 0.000 claims description 8
- 235000013974 saffron Nutrition 0.000 claims description 8
- 239000004248 saffron Substances 0.000 claims description 8
- 229940076591 saffron extract Drugs 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 238000006386 neutralization reaction Methods 0.000 claims description 6
- 230000036542 oxidative stress Effects 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 2
- 239000012141 concentrate Substances 0.000 claims 1
- SEBIKDIMAPSUBY-ARYZWOCPSA-N Crocin Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC(=O)C(C)=CC=CC(C)=C\C=C\C=C(/C)\C=C\C=C(C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1)O)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SEBIKDIMAPSUBY-ARYZWOCPSA-N 0.000 abstract description 46
- SEBIKDIMAPSUBY-JAUCNNNOSA-N Crocin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C(=O)OC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O)C=CC=C(/C)C(=O)OC3OC(COC4OC(CO)C(O)C(O)C4O)C(O)C(O)C3O SEBIKDIMAPSUBY-JAUCNNNOSA-N 0.000 abstract description 46
- 239000003513 alkali Substances 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 6
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 abstract description 3
- 230000003647 oxidation Effects 0.000 abstract description 3
- 238000007254 oxidation reaction Methods 0.000 abstract description 3
- 230000004792 oxidative damage Effects 0.000 description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 201000010099 disease Diseases 0.000 description 8
- AJBZENLMTKDAEK-UHFFFAOYSA-N 3a,5a,5b,8,8,11a-hexamethyl-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysene-4,9-diol Chemical compound CC12CCC(O)C(C)(C)C1CCC(C1(C)CC3O)(C)C2CCC1C1C3(C)CCC1C(=C)C AJBZENLMTKDAEK-UHFFFAOYSA-N 0.000 description 7
- 241000132025 Calendula Species 0.000 description 7
- 235000003880 Calendula Nutrition 0.000 description 7
- 241000282414 Homo sapiens Species 0.000 description 7
- 239000000203 mixture Substances 0.000 description 6
- 206010064930 age-related macular degeneration Diseases 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000005303 weighing Methods 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 235000004237 Crocus Nutrition 0.000 description 4
- 241000596148 Crocus Species 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- 238000004108 freeze drying Methods 0.000 description 4
- 235000012680 lutein Nutrition 0.000 description 4
- 239000001656 lutein Substances 0.000 description 4
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 4
- 229960005375 lutein Drugs 0.000 description 4
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 4
- 208000002780 macular degeneration Diseases 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 230000002207 retinal effect Effects 0.000 description 4
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 4
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 241000157835 Gardenia Species 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 210000001525 retina Anatomy 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 208000035719 Maculopathy Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108010009736 Protein Hydrolysates Proteins 0.000 description 2
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Substances CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 208000003464 asthenopia Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004155 blood-retinal barrier Anatomy 0.000 description 1
- 230000004378 blood-retinal barrier Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 210000003161 choroid Anatomy 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- ZVGODNZUEWDIPM-PMPQWGFGSA-N crocetin beta-D-glucopyranosyl ester Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C(=O)OC1OC(CO)C(O)C(O)C1O)C=CC=C(/C)C(=O)O ZVGODNZUEWDIPM-PMPQWGFGSA-N 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000000401 methanolic extract Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 210000000608 photoreceptor cell Anatomy 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 210000003583 retinal pigment epithelium Anatomy 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- -1 troches Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/42—Separation; Purification; Stabilisation; Use of additives
- C07C51/48—Separation; Purification; Stabilisation; Use of additives by liquid-liquid treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention provides a preparation method of crocin acid and an anti-oxidation eye protection application, wherein the preparation method of crocin extraction hydrolysate containing high-content crocin acid comprises crocin crushing, ethanol water solution extraction and alkali hydrolysis to obtain crocin extract containing crocin, and crocin hydrolysate containing high-content crocin acid can be obtained after hydrolysis, so that the crocin hydrolysate has an eye protection effect and can effectively improve the survival rate of retinal pigment epithelial cells subjected to oxidation pressure.
Description
Technical Field
The invention relates to the technical field of crocetin preparation methods, in particular to a crocetin preparation method and an antioxidant eye protection application.
Background
Eye diseases are commonly found in retinopathy, glaucoma and Age-related macular degeneration (Age-related macular degeneration, AMD) caused by diabetes, and the main cause of AMD is maculopathy caused by oxidative damage of retinal pigment epithelial cells due to imbalance of active oxygen in the eye. AMD is a pathogenesis of excessive reactive oxygen species that interfere with the normal function of retinal epithelial cells, and reduce the integrity of the retinal pigment epithelial cell junctions, leading to apoptosis.
Retinal pigment epithelial cells (retinal pigment epithelium, RPE) are a monolayer of cells located between the photoreceptor cells and the choroid of the neural retinal layer. Functionally playing the role of an outer blood-retinal barrier (outer) and the close association (light junction) of endothelial cell formation are critical for transporting fluids or substances across the barrier, so RPE cells have the function of maintaining retinal layer integrity.
Reactive oxygen species are relatively reactive oxygen-containing molecules, generally referred to as oxygen-containing free radicals and non-free radicals. Non-radical molecules are rapidly converted to free radicals when subjected to oxidation. Hydrogen peroxide (hydrogen peroxide, H) 2 O 2 ) Is an active oxygen species, has high polarity, does not have unpaired electrons, but is an intermediate product formed by oxygen free radicals; can flow and spread in cells or among cells, causing oxidative damage to the cells.
Lutein is currently the most common eye care food, but can only bring partial benefit to retina and can not provide complete protection to retina, scientists still continuously search for components with better eye care effect.
Crocin (Crocetin) is carotenoid with small molecule, can be absorbed by human body rapidly, can relieve eye fatigue, and can be obtained by converting Crocin (Crocin) extracted from Crocin with complicated steps. The mechanism of crocetin for ocular protection has not been fully elucidated in the current studies.
There are many improvements in crocetin extraction technology today. Chinese patent CN106905145a discloses a method for extracting crocetin, wherein the gardenia extract uses 4% sodium hydroxide aqueous solution, hydrolyzes for 2.5 hours, the crocetin content in the crude crocetin product is only 10.6%, and the crocetin product needs to be crystallized by using 10% sodium hydroxide aqueous solution and leached by methanol, so that the crocetin with higher purity can be obtained, and the prior art needs not only the step of twice alkali treatment with different concentrations, but also the step of using high concentration alkali; chinese patent CN108203378A discloses a method for extracting crocetin, wherein the gardenia extract is hydrolyzed by potassium hydroxide, neutralized by adding acid, then heated and stirred by adding methanol, filtering, adding a filter cake into acetone for crystallization to obtain high-purity crocetin, and high-concentration alkali, organic solution methanol and acetone are needed in the process; chinese patent CN103695494B discloses a method for extracting crocetin, which uses gardenia methanol extract as raw material, and only crude product with crocetin content of only 10.6% can be obtained through alkali hydrolysis and ultrasonic acceleration; the product of crocetin with high purity can be obtained by secondary alkaline hydrolysis and secondary enzyme catalysis. As can be seen from the foregoing patent, the prior art for preparing crocetin requires complicated steps, besides alkaline hydrolysis, crystallization with strong alkali or organic solvent or enzyme action, and can obtain high purity crocetin, and various organic solvents or high concentration alkali are used in the process, which may remain in the finished product to cause toxicity or may cause long-term harm on the body of the extractor in the extraction process.
Therefore, the invention provides a simple and safe method for extracting crocetin, and confirms that the crocetin has antioxidant eye protection purpose.
Disclosure of Invention
In view of the above, the present inventors have succeeded in developing and completing a simple and safe preparation method of crocetin through improvement and innovation of many years of research, comprising the following steps:
step one: crushing saffron;
step two: adding a first ethanol aqueous solution for extraction, and filtering to obtain a saffron extract, wherein the first ethanol aqueous solution contains 40-60 wt% of ethanol, the extraction temperature is 40-60 ℃, and the extraction time is 5-7 hours;
step three: the crocus sativus extract is prepared in a second ethanol aqueous solution, and sodium hydroxide is added for hydrolysis, wherein the second ethanol aqueous solution contains 12-30wt% of ethanol, the hydrolysis temperature is 65-85 ℃, and the hydrolysis time is 1.5-3 hours;
step four: adding hydrochloric acid for neutralization to obtain a saffron hydrolysate; the crocus sativus hydrolysate contains high crocus sativus acid content, and after drying, the crocus sativus hydrolysate contains 13-20 mg crocus sativus acid per gram.
To achieve the above object, the saffron extract is further concentrated to obtain a saffron concentrated extract or freeze-dried to obtain a saffron extract powder, and then the saffron extract powder is placed in the second ethanol aqueous solution.
To achieve the above object, the weight ratio of the crocus sativus to the first ethanol aqueous solution is (1:40) - (1:60).
To achieve the above object, the weight ratio of the crocus sativus extract to the second aqueous ethanol solution is (1:8) - (1:13).
To achieve the above object, the weight ratio of the crocus sativus concentrated extract to the second ethanol aqueous solution is (1:8) - (1:13); the weight ratio of the crocus sativus extract powder to the second aqueous ethanol solution is (1:8) - (1:13).
To achieve the above object, the weight ratio of the second ethanol aqueous solution to the sodium hydroxide is 35: 1) And (3) the following steps: 1).
To achieve the above object, the crocus sativus hydrolysate is freeze-dried to obtain a crocus sativus hydrolysate powder, wherein each gram of crocus sativus hydrolysate powder contains 15-18 mg of crocus sativus acid.
The invention further provides the use of crocetin for the preparation of a pharmaceutical composition for eye protection.
To achieve the above object, the crocetin is obtained from crocus sativus through the preparation method described above.
To achieve the above object, wherein protecting eyes means effectively improving survival rate of retinal pigment epithelial cells subjected to oxidative stress
To achieve the above object, the effective concentration of crocetin is 6 mug/mL-200 mug/mL.
To achieve the above object, the effective concentration of crocetin is 8 mug/mL-100 mug/mL.
In summary, the present invention provides a simple and safe method for extracting crocetin, which can obtain high crocin and crocetin content without using harmful organic solvents, protect eyes and effectively improve survival rate of retinal pigment epithelial cells subjected to oxidative stress.
Drawings
FIG. 1 is a flow chart of a process for preparing crocus sativus hydrolysate containing high levels of crocus sativus acid.
Fig. 2A is an HPLC profile of crocin standard and crocin acid standard.
Fig. 2B is an HPLC profile of crocus sativus extract and crocus sativus hydrolysate.
FIG. 3A shows crocus sativus hydrolysate pair H 2 O 2 Influence of oxidative damage on retinal pigment epithelial cells (mean P)<0.05)。
FIG. 3B shows crocus sativus extract pair H 2 O 2 Influence of oxidative damage on retinal pigment epithelial cells (mean P)<0.05)。
FIG. 3C is calendula extract pair H 2 O 2 Influence of oxidative damage on retinal pigment epithelial cells (mean P)<0.05)。
Detailed Description
[ definition of terms ]
In the following description, the following definitions are provided for a clear and consistent understanding of the present specification and claims, as well as the scope of the terms that are assigned thereto, as a result of which many technical and scientific terms that are conventional in the biotechnology arts are widely used in this specification. Other terms, not specifically defined below, are to be construed as commonly understood by one of ordinary skill in the art.
The term "individual" refers to any mammal in need of or believed to potentially require the crocetin-containing crocetin hydrolysate of the present invention that contains primates, rodents, pets, laboratory test animals, and wild animals. For example, this may include, but is not limited to: monkey, human, pig, cow, sheep, goat, equine, mouse, rat, guinea pig, hamster, rabbit, cat (felines), dog (cannines). Preferably, the subject is a mouse or a human.
The term "treatment" and the like is used herein to administer an agent in order to achieve a certain effect. The effect is a therapeutic partial or complete effective cure of a disease and/or symptoms of the disease.
The terms "therapeutically effective amount," "therapeutic dose," and the like are used herein to treat, cure, prevent, or ameliorate a disease, disorder, or side effect, or to reduce the rate of progression of a disease or disorder. The term also includes within its scope an amount effective to enhance normal physiological function.
The term "pharmaceutically acceptable" means that the substance or composition must be compatible with the other ingredients of the pharmaceutical formulation thereof and not exacerbate the symptoms of the patient.
The pharmaceutical composition provided by the invention can be prepared into a dosage form suitable for the composition by utilizing the technology known to a person with ordinary skill in the art to which the invention belongs, and the active ingredient or the composition provided by the invention and at least one pharmaceutically acceptable carrier (vehicle). Wherein the dosage form includes, but is not limited to, solutions, emulsions, suspensions, powders, lozenges, troches, tablets, chewing gums, capsules, and other similar or suitable dosage forms for the present invention.
The term "pharmaceutically acceptable carrier" includes one or more types of ingredients selected from the group consisting of: solvents, emulsifiers, suspending agents, disintegrants, binders, excipients, stabilizers, chelating agents, diluents, gelling agents, preservatives, lubricants, surfactants, and other similar or suitable carriers for the invention.
One or more of dissolution aids, buffers, colorants, flavors, and the like which are generally used in the field of preparation may be added to the above composition as needed.
The term "pharmaceutically acceptable excipient" includes, but is not limited to, at least one of polymers, resins, plasticizers, fillers, lubricants, diluents, binders, disintegrants, solvents, co-solvents, surfactants, preservatives, sweeteners, flavoring agents, pharmaceutical grade dyes or pigments, and viscosity agents.
The term "cell culture" and the like are used herein to maintain cells in an artificial in vitro environment. However, it should be understood that the term "cell culture" is a generic term and can be used to encompass not only the cultivation of individual cells, but also the cultivation of tissues or organs.
The methods of the present invention relate to administering crocus hydrolysates containing high levels of crocus acid to an individual (e.g., a human patient) to protect the eyes from oxidative damage. The methods of treatment according to the methods of the invention may also treat, cure, alleviate, alter, remedy, ameliorate, augment or affect the disease, the symptoms or conditions of the disease, the disability caused by the disease, or the progression of the disease.
[ administration of crocus sativus hydrolysate containing high crocus sativus acid ]
The pharmaceutical compositions of the invention may be delivered by any physiologically acceptable route and may be administered topically or systemically, with or without the addition of excipients, such as orally, parenterally (e.g., intramuscularly, intravenously, subcutaneously, and intraperitoneally), transdermally, suppository, ophthalmic, and intranasal.
[ dose ]
In the methods of treatment of the present invention, an effective amount of crocus sativus hydrolysate containing a high level of crocus sativus acid is administered to a subject in need thereof. In particular, the type of crocus sativus hydrolysate containing a high level of crocus sativus acid will vary depending on the purpose of administration, the health and physical condition of the individual to be treated, the age, the taxonomic group of individuals to be treated (e.g., human, non-human primate, etc.), the evaluation of the medical condition by the treating clinician, and other relevant factors. It is expected that this amount will be within a relatively wide range, which can be determined via routine experimentation.
[ pharmaceutical composition ]
Crocus sativus hydrolysates containing high levels of crocus sativus acid can be mixed with pharmaceutically acceptable carriers to prepare pharmaceutical compositions; can also be packaged in a container and prepared into a kit or product together with a package insert which records information related to the crocus sativus extract, the method of use, etc.
The present invention is illustrated by the following examples, which are, however, merely illustrative of the present invention and should not be construed as limiting the scope of the invention in any way, and in addition, all materials used herein are readily available from commercial sources.
Referring to fig. 1, according to an embodiment of the present invention, there is provided a method for producing crocus sativus hydrolysate containing crocus sativus acid in high content, comprising the steps of (S1) pulverizing crocus sativus; (S2) adding 40-60 wt% ethanol water solution for extraction at 40-60 ℃ for 5-7 hours, and filtering to obtain a saffron extract; (S3) preparing the crocus sativus extract into 12-30wt% ethanol water solution, adding sodium hydroxide for hydrolysis, wherein the hydrolysis temperature is 65-85 ℃ and the hydrolysis time is 1.5-3 hours; (S4) adding hydrochloric acid for neutralization to obtain the saffron hydrolysate.
Example one, crocus sativus extraction method
Crushing crocus sativus, adding a first ethanol aqueous solution with the weight being 40-60 times that of the crocus sativus, placing the solution for extraction for 5-7 hours at the extraction temperature of 40-60 ℃, filtering to retain liquid, concentrating the filtrate in vacuum to obtain crocus sativus extract, freeze-drying to obtain crocus sativus extract powder, adding a second ethanol aqueous solution with the weight being 8-13 times that of the crocus sativus extract powder, wherein the second ethanol aqueous solution contains 12-30% of ethanol, adding sodium hydroxide (30-50 g/L), placing the solution in the hydrolysis temperature of 70-80 ℃ for hydrolysis for 1.5-3 hours, adding hydrochloric acid for neutralization to obtain crocus sativus hydrolysate, and freeze-drying to obtain crocus sativus hydrolysate powder.
The amount of the first ethanol aqueous solution is preferably 50 times the weight of the crocus sativus; the first ethanol aqueous solution is preferably 50wt% ethanol; the extraction temperature is optimized at 50 ℃; the extraction time was optimal at 6 hours.
In the example, 30g of crocus sativus is weighed, 1500ml of 50% ethanol is added, extraction is carried out for 6 hours at 50 ℃, and after the filtrate is concentrated in vacuum, the crocus sativus extract powder is obtained after freeze drying.
The dosage of the second ethanol aqueous solution is 10.4 times of the weight of the crocus sativus extract powder; the second ethanol aqueous solution is preferably 20wt% ethanol; the dosage of sodium hydroxide is optimally 40 g/L; the hydrolysis temperature is optimal at 75 ℃, and the hydrolysis time is optimal at 2 hours; hydrochloric acid for neutralization is preferably used at a concentration of 12M.
In the example, 9.6g of crocus sativus extract powder is weighed, 100mL of 20% ethanol is added, naOH (40 g/L) is added, hydrolysis is carried out for 2 hours at 75 ℃, 12M HCl (6 mL) is added for neutralization, and freeze drying is carried out, thus obtaining crocus sativus hydrolysate powder.
Example two, crocus sativus extract and analysis of the content of hydrolysate thereof
HPLC analysis conditions:
chromatographic column: inertsil 250X 4.6 mm i.d.5 microns;
detection wavelength: 440nm;
column temperature: 35 ℃;
mobile phase: a-0.1% formic acid aqueous solution, B-acetonitrile, C-methanol;
flow rate: 0.8 milliliters per minute;
and (3) gradient stripping: as shown in Table 1
TABLE 1
Time (minutes) | %A | %B | %C |
0 | 80 | 20 | 0 |
18 | 65 | 35 | 0 |
23 | 25 | 75 | 0 |
36 | 12 | 0 | 88 |
40 | 12 | 0 | 88 |
41 | 0 | 0 | 100 |
Crocin (Crocin) standard formulation: weighing crocin 5 mg, placing in a 50 ml quantitative bottle, adding 50% ethanol to scale, filtering to obtain 0.45 micrometer filter membrane, and injecting into 10 microliters.
Crocetin (Crocetin) standard formulation: weighing crocetin 5 mg, placing into a 50 ml quantitative bottle, adding 50% ethanol to the scale, weighing the 5ml of crocetin to 10 ml with methanol, filtering with 0.45 micrometer filter membrane, and injecting 10 microliters.
Preparing crocus sativus extract: weighing 4 mg of crocus sativus extract powder, placing in a 50 ml quantitative bottle, adding 50% ethanol to the scale, filtering with 0.45 μm filter membrane, and injecting into 10 microliters.
Preparing crocus sativus hydrolysate: weighing crocus sativus hydrolysate powder 25 mg, placing in 50 ml quantitative bottle, adding 50% ethanol to scale, filtering with 0.45 micrometer filter membrane, and injecting into 10 microliters.
Conversion calculation:
C a : total amount of Crocetin (Crocetin) after hydrolysis;
C b : total amount of Crocin (Crocin) before hydrolysis;
MW 2 : crocetin (Crocetin) molecular weight 328.4;
MW 1 : crocin (Crocin) molecular weight 977.0;
FIG. 2A is an HPLC chromatographic chart of Crocin (Crocin) and Crocin (Crocin) standard, 9.6g of unhydrolyzed Crocin extract powder is taken, 7.67g of Crocin hydrolysate powder is obtained after hydrolysis, and according to the HPLC analysis result, the Crocin extract chart in FIG. 2B is marked as Crocin extract (before hydrolysis), the Crocin (Crocin) content in the Crocin extract prepared from the Crocin extract powder is 52.2mg/g, wherein Crocin is not detected; the Crocin hydrolysate pattern in FIG. 2B was designated as Crocin extract (after hydrolysis) and Crocin hydrolysate powder was formulated to have a Crocin acid (Crocin) content of 16.7mg/g, crocin was not detected in Crocin hydrolysate, and the conversion was calculated to be 76.33%.
Example III, crocus sativus extract, crocus sativus hydrolysate protective action on retinal pigment epithelial cells
[H 2 O 2 Oxidative injury cell experiment]Human retinal pigment epithelial cells (ARPE-19) were cultured in 24 well (well) microplates at a cell density of 3X 10 4 cell/well, 5% CO at 37deg.C 2 Culturing in an incubator for 24 hours, and pasting ARPE-19 cells on the dish. Then removing the old culture solution, adding 0.5mL of cell culture solution containing test samples with different concentrations, culturing for 24 hours, removing the culture solution containing the test samples, and then adding the culture solution containing 1mM H 2 O 2 Is cultured for 3 hours to cause oxidative damage, the culture solution is sucked off, and 0.4mL of a medium containing 1mg/mL MTT (light shielding in CO is required) is added to each well 2 The reaction was carried out in an incubator for 2 hours, the medium containing MTT reagent was removed, 0.4mL of DMSO was added thereto, and the crystals were dissolved uniformly by shaking, and the absorbance was measured at 570nm by ELISA reader, and the cell viability was calculated.
The purpose of this experiment was to investigate the H pair of crocus sativus extracts before and after hydrolysis 2 O 2 Protection against oxidative damage of retinal pigment epithelial cells (ARPE-19) was achieved with calendula extract containing 5% lutein as control.
FIG. 3A shows that the crocus sativus hydrolysate sample prepared from crocus sativus hydrolysate powder can reduce oxidation injury of retinal cells, and can significantly reduce H at concentration of more than 10 μg/mL 2 O 2 The resulting oxidative damage was 31% less oxidative damage at 10 μg/mL, 53% less oxidative damage at 25 μg/mL, 79% less oxidative damage at 50 μg/mL, and dose-effect correlation.
FIG. 3B shows that samples of crocus sativus extract formulated from crocus sativus extract powder significantly reduced H at concentrations above 25 μg/mL 2 O 2 The resulting oxidative damage was 41% reduced with 25 μg/mL and 63% reduced with 50 μg/mL, and a dose-effect correlation was established.
FIG. 3C shows that the calendula extract samples used as the control group increased H-channel 2 O 2 Reduced cell viability of oxidative damage, calendula extract at maximum test concentration (50 μg/mL) was significantly reduced visionEffect of oxidative damage of omental pigment epithelial cells 57%.
From the above results, it was found that the crocin hydrolysate (containing crocin), crocin extract (containing crocin), calendula extract (containing 5% lutein) can improve the H-channel 2 O 2 Reduced cell viability with oxidative damage, with the best results with crocus hydrolysates containing high levels of crocetin, the next-second crocus extracts, and the worst calendula extracts.
In view of the above, the present invention provides a simple and safe process for extracting crocetin, which can obtain crocetin hydrolysate containing high crocetin content without using harmful organic solvents; at the same dose, the protection effect of the crocus sativus extract (unhydrolyzed and hydrolyzed) on the oxidative damage of the retina cells is better than that of the calendula extract (containing 5% of lutein), and the crocus sativus hydrolysate containing high crocus sativus acid has the potential of developing health care raw materials for protecting eyes and preventing maculopathy.
The above embodiments are provided to illustrate the technical spirit and features of the present invention, and to enable those skilled in the art to understand the present invention and to implement it according to the present invention, and should not limit the scope of the present invention, i.e. all equivalent changes or modifications that are substantially in accordance with the spirit of the present invention are included in the scope of the present invention.
[ PREPARATION ] S1-S4.
Claims (12)
1. A method for preparing crocetin, comprising the steps of:
step one: crushing saffron;
step two: adding a first ethanol aqueous solution for extraction, and filtering to obtain a saffron extract, wherein the first ethanol aqueous solution contains 40-60 wt% of ethanol, the extraction temperature is 40-60 ℃, and the extraction time is 5-7 hours;
step three: the crocus sativus extract is arranged in a second ethanol aqueous solution, sodium hydroxide is added for hydrolysis, the second ethanol aqueous solution contains 12-30wt% of ethanol, the hydrolysis temperature is 65-85 ℃, and the hydrolysis time is 1.5-3 hours;
step four: adding hydrochloric acid for neutralization to obtain a saffron hydrolysate; the crocus sativus hydrolysate contains crocus sativus acid, and the crocus sativus hydrolysate contains 13-20 mg of crocus sativus acid per gram after being dried.
2. The method of claim 1, wherein the saffron extract is further subjected to liquid concentration to obtain a saffron concentrated extract or freeze-dried to obtain a saffron extract powder, and is further disposed in the second aqueous ethanol solution.
3. The method of claim 1, wherein the weight ratio of crocus sativus to the first aqueous ethanol solution is from (1:40) to (1:60).
4. The method of claim 1, wherein the weight ratio of the crocus sativus extract to the second aqueous ethanol solution is from (1:8) to (1:13).
5. The method of claim 2, wherein the weight ratio of the saffron concentrate extract to the second aqueous ethanol solution is from (1:8) to (1:13); the weight ratio of the crocus sativus extract powder to the second ethanol aqueous solution is (1:8) - (1:13).
6. The method of claim 1, wherein the weight ratio of the second aqueous ethanol solution to the sodium hydroxide is (35:1) - (20:1).
7. The method of claim 1, wherein said crocus sativus hydrolysate is freeze-dried to provide a crocus sativus hydrolysate powder comprising from 15 mg to 18 mg crocus sativus acid per gram of said crocus sativus hydrolysate powder.
8. Use of crocetin for the preparation of a pharmaceutical composition for protecting the eye, wherein protecting the eye is effective to increase the survival rate of retinal pigment epithelial cells subjected to oxidative stress.
9. Use according to claim 8, characterized in that the crocetin is obtained from crocus sativus via the preparation method according to claim 1.
10. The use according to claim 8, wherein the protection of the eye is effective to increase survival of retinal pigment epithelial cells subjected to oxidative stress.
11. The use according to claim 8, wherein the effective concentration of crocetin is between 6 μg/mL and 200 μg/mL.
12. The use according to claim 8, wherein the effective concentration of crocetin is between 8 μg/mL and 100 μg/mL.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TW111116758 | 2022-05-04 | ||
TW111116758A TW202344245A (en) | 2022-05-04 | 2022-05-04 | Method of preparing crocetin and application of antioxidant for eye protection improving the survival rate of retinal pigment epithelium suffering from oxidative stress |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117049960A true CN117049960A (en) | 2023-11-14 |
Family
ID=88655980
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210522534.5A Pending CN117049960A (en) | 2022-05-04 | 2022-05-13 | Preparation method of crocetin and application of crocetin in antioxidation and eye protection |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN117049960A (en) |
TW (1) | TW202344245A (en) |
-
2022
- 2022-05-04 TW TW111116758A patent/TW202344245A/en unknown
- 2022-05-13 CN CN202210522534.5A patent/CN117049960A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
TW202344245A (en) | 2023-11-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5538611B2 (en) | Maillard reaction inhibitor | |
JPH08500589A (en) | Astragalus Polysaccharide Immunomodulator | |
KR101467903B1 (en) | The preparing method of immune improving agents | |
CN103462025A (en) | Health food assisting in reducing blood fat and preparation method and application thereof | |
KR19990014205A (en) | Compositions Containing Flavonoids and Papia Workpieces | |
CN105983015B (en) | A pharmaceutical composition containing silibinin and VE | |
JP6600626B2 (en) | Methods for obtaining plant extracts and related compositions | |
JPWO2017135466A1 (en) | A composition containing xanthophyll and a processed plant of the genus Hishi | |
US20240139281A1 (en) | Use of goji glycopeptide in preparation of drug for preventing and/or treating amyotrophic lateral sclerosis | |
CN108135951B (en) | Composition for preventing hair loss or promoting hair growth containing exopolysaccharide produced by Ceriporia lacerata as effective component | |
CN110577976A (en) | Mung bean oligopeptide powder and preparation method thereof | |
US20170136075A1 (en) | Pharmaceutical composition containing spirulina maxima extract as active ingredient for preventing and treating retinal diseases | |
TWI678210B (en) | Use of water extract or ethanol extract of cordyceps cicadae for preventing,delaying or treating cataract | |
JP6148780B1 (en) | A composition containing xanthophyll and a processed plant of the genus Hishi | |
CN117049960A (en) | Preparation method of crocetin and application of crocetin in antioxidation and eye protection | |
CN110856744B (en) | New application of dendrobe polypeptide | |
TW202315643A (en) | Use of extract of fruit body ofcordyceps militarisfor manufacturing medication for improving anti-blue light damage effect | |
CN110946986B (en) | Application of oligopeptide in preparation of medicine for preventing and treating non-alcoholic fatty liver disease | |
JP4863870B2 (en) | Antiallergic agent | |
CN113234178A (en) | Nostoc sphaeroids kutz oligosaccharide and preparation method and application thereof | |
US10357525B2 (en) | Use of a polysaccharide mixture for treating hyperglycemia | |
US11179408B2 (en) | Use of cyanoglucosides and pharmaceutical formulations thereof in the treatment of diabetes | |
KR101343367B1 (en) | Compositions comprising lichen-forming fungi or scytalone for preventing and treating diabetes mellitus | |
JP2004099613A (en) | Ganoderma lucidum spores for treatment of autoimmune diseases | |
CN111317822B (en) | Combined preparation containing flavone and immunoregulation peptide, preparation method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |